PepGen Secures Operations into 2H 2027 with $132.3M Cash, Covering Key Clinical Readout
PEPG sits 65% above its 52-week low of $1.01.
Summary
PepGen Inc. announced a strong cash position of $132.3 million as of March 31, which the company states is sufficient to fund operations through the FREEDOM2 12.5 Mg/kg MAD readout and into the second half of 2027. This update provides crucial clarity on the company's financial runway, especially following the highly dilutive $107.6 million equity offering disclosed in its March 4, 2026 10-K. For a clinical-stage biotech, securing funding through a significant clinical milestone like the FREEDOM2 readout significantly de-risks the investment by alleviating immediate concerns about future dilution. Traders will now shift focus to the upcoming clinical data, with the company's financial stability secured for the foreseeable future.
At the time of this announcement, PEPG was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $116.1M. The 52-week trading range was $1.01 to $7.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.